Jason Hawkes, MD, MS, a Dermatologist and Investigator at Oregon Medical Research Center in Portland, OR, discusses the significance and implications of the U.S. Food and Drug Administration’s approval of dupilumab (Dupixent, Sanofi & Regeneron) for patients aged 12+ years with uncontrolled Chronic Spontaneous Urticaria (CSU) who remain symptomatic despite use of H1-antihistamines. “It’s a win in dermatology because these are patients that we can easily recognize and diagnose, and now we have a familiar therapy that we know has had this robust effect on type 2 Inflammation, is very well-tolerated, and has an excellent safety record,” he says. “And now we have really broadening of a mechanism of action that might help treat a larger proportion of these patients.”
